Home

vezetés Fogazott zsolozsma abemaciclib overall survival A fején bosszantani Kezdő

Overall survival in the ITT population and by subgroup. a Kaplan-Meier... |  Download Scientific Diagram
Overall survival in the ITT population and by subgroup. a Kaplan-Meier... | Download Scientific Diagram

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal  growth factor receptor 2-negative advanced breast cancer in premenopausal  women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research  | Full Text
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text

Real-world time trends in overall survival, treatments and patient  characteristics in HR+/HER2− metastatic breast cancer: an observational  study of the SONABRE Registry - The Lancet Regional Health – Europe
Real-world time trends in overall survival, treatments and patient characteristics in HR+/HER2− metastatic breast cancer: an observational study of the SONABRE Registry - The Lancet Regional Health – Europe

Abemaciclib plus endocrine therapy for hormone receptor-positive,  HER2-negative, node-positive, high-risk early breast cancer (monarchE):  results from a preplanned interim analysis of a randomised, open-label,  phase 3 trial - The Lancet Oncology
Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial - The Lancet Oncology

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With  HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving  Endocrine Therapy. | Semantic Scholar
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. | Semantic Scholar

Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal  growth factor receptor 2-negative advanced breast cancer in premenopausal  women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research  | Full Text
Abemaciclib plus fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in premenopausal women: subgroup analysis from the MONARCH 2 trial | Breast Cancer Research | Full Text

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy  for advanced breast cancer | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer

IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in  Real-World Data: A Direct Comparison of First-Line Treatment for  Endocrine-Receptor-Positive Metastatic Breast Cancer
IJMS | Free Full-Text | Abemaciclib, Palbociclib, and Ribociclib in Real-World Data: A Direct Comparison of First-Line Treatment for Endocrine-Receptor-Positive Metastatic Breast Cancer

Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as  initial therapy for patients with hormone receptor-positive, human  epidermal growth factor receptor 2-negative advanced breast cancer |  SpringerLink
Japanese subgroup analysis of the phase 3 MONARCH 3 study of abemaciclib as initial therapy for patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer | SpringerLink

Progression-free survival. a Investigator-assessed and b Independent... |  Download Scientific Diagram
Progression-free survival. a Investigator-assessed and b Independent... | Download Scientific Diagram

PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in  Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on  Endocrine Therapy—MONARCH 2 | Semantic Scholar
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar

ESMO-BC 2023: Results in Chinese patients from pre-planned overall survival  interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy  for high risk HR+, HER2- early breast cancer
ESMO-BC 2023: Results in Chinese patients from pre-planned overall survival interim analysis in monarchE: Abemaciclib plus adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer

Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic  breast cancer | Future Oncology
Abemaciclib, a CDK4 and CDK6 inhibitor for the treatment of metastatic breast cancer | Future Oncology

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy  for advanced breast cancer | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer

PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in  Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on  Endocrine Therapy—MONARCH 2 | Semantic Scholar
PDF] The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2 | Semantic Scholar

Developments in Advanced Breast Cancer Treatment | EMJ Reviews
Developments in Advanced Breast Cancer Treatment | EMJ Reviews

PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus  Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced  Breast Cancer | Semantic Scholar
PDF] MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer | Semantic Scholar

SABCS 2022: Abemaciclib plus endocrine therapy for HR+, HER2-,  node-positive, high-risk early breast cancer: results from a pre-planned  monarchE overall survival interim analysis, including 4-year efficacy  outcomes
SABCS 2022: Abemaciclib plus endocrine therapy for HR+, HER2-, node-positive, high-risk early breast cancer: results from a pre-planned monarchE overall survival interim analysis, including 4-year efficacy outcomes

Update Shows Long-Term Survival Benefit with Abemaciclib Plus
Update Shows Long-Term Survival Benefit with Abemaciclib Plus

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy  for advanced breast cancer | npj Breast Cancer
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer | npj Breast Cancer

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3  updated results in prognostic subgroups | npj Breast Cancer
Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups | npj Breast Cancer

Management of Abemaciclib‐Associated Adverse Events in Patients with  Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor  2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH  3 - Rugo - 2021 -
Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3 - Rugo - 2021 -

SABCS 2022: Final overall survival analysis of Monarch 2 : A phase 3 trial  of Abemaciclib plus Fulvestrant in patients with hormone receptor-positive,  HER2-negative advanced breast cancer
SABCS 2022: Final overall survival analysis of Monarch 2 : A phase 3 trial of Abemaciclib plus Fulvestrant in patients with hormone receptor-positive, HER2-negative advanced breast cancer

Abemaciclib regimen shows further signs of benefit in advanced breast  cancer subgroup
Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup